CA2939639C - Uti fusion proteins - Google Patents

Uti fusion proteins Download PDF

Info

Publication number
CA2939639C
CA2939639C CA2939639A CA2939639A CA2939639C CA 2939639 C CA2939639 C CA 2939639C CA 2939639 A CA2939639 A CA 2939639A CA 2939639 A CA2939639 A CA 2939639A CA 2939639 C CA2939639 C CA 2939639C
Authority
CA
Canada
Prior art keywords
uti
fusion protein
domain
cell
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2939639A
Other languages
English (en)
French (fr)
Other versions
CA2939639A1 (en
Inventor
Aaron Chamberlain
Qiang Liu
Mathias Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda GmbH
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda GmbH, Takeda Pharmaceutical Co Ltd filed Critical Takeda GmbH
Priority to CA3178241A priority Critical patent/CA3178241A1/en
Publication of CA2939639A1 publication Critical patent/CA2939639A1/en
Application granted granted Critical
Publication of CA2939639C publication Critical patent/CA2939639C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
CA2939639A 2014-02-24 2015-02-23 Uti fusion proteins Active CA2939639C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3178241A CA3178241A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
US61/943,617 2014-02-24
PCT/US2015/017152 WO2015127391A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3178241A Division CA3178241A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Publications (2)

Publication Number Publication Date
CA2939639A1 CA2939639A1 (en) 2015-08-27
CA2939639C true CA2939639C (en) 2023-01-24

Family

ID=52629709

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2939639A Active CA2939639C (en) 2014-02-24 2015-02-23 Uti fusion proteins
CA3178241A Pending CA3178241A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3178241A Pending CA3178241A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Country Status (38)

Country Link
US (4) US9856310B2 (enExample)
EP (2) EP3110434B1 (enExample)
JP (4) JP6574431B2 (enExample)
KR (3) KR102722304B1 (enExample)
CN (2) CN106232135B (enExample)
AR (1) AR101597A1 (enExample)
AU (4) AU2015218704B2 (enExample)
BR (1) BR112016019390B1 (enExample)
CA (2) CA2939639C (enExample)
CL (1) CL2016002136A1 (enExample)
CR (1) CR20160444A (enExample)
CY (1) CY1120997T1 (enExample)
DK (1) DK3110434T3 (enExample)
DO (1) DOP2016000202A (enExample)
EA (2) EA037256B1 (enExample)
EC (1) ECSP16076535A (enExample)
ES (1) ES2700149T3 (enExample)
GE (2) GEP20196970B (enExample)
HR (1) HRP20182029T1 (enExample)
IL (1) IL247321B (enExample)
JO (1) JO3729B1 (enExample)
LT (1) LT3110434T (enExample)
MA (1) MA39347B2 (enExample)
MX (4) MX384070B (enExample)
MY (1) MY178774A (enExample)
NZ (3) NZ760008A (enExample)
PE (1) PE20170257A1 (enExample)
PH (1) PH12016501629B1 (enExample)
PL (1) PL3110434T3 (enExample)
PT (1) PT3110434T (enExample)
RS (1) RS58285B1 (enExample)
SG (2) SG10201708400QA (enExample)
SI (1) SI3110434T1 (enExample)
SM (1) SMT201800674T1 (enExample)
TW (1) TWI694084B (enExample)
UA (1) UA118866C2 (enExample)
WO (1) WO2015127391A1 (enExample)
ZA (1) ZA201606327B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939639C (en) * 2014-02-24 2023-01-24 Takeda Gmbh Uti fusion proteins
WO2018226887A1 (en) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
WO2020106881A1 (en) * 2018-11-20 2020-05-28 Diamedica Inc. Modified ulinastatin polypeptides
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
JP7778077B2 (ja) * 2020-03-05 2025-12-01 ダイアメディカ ユーエスエー インコーポレイテッド ウリナスタチンポリペプチド
WO2022165031A1 (en) * 2021-01-29 2022-08-04 DiaMedica USA Inc. Ulinastatin polypeptides for treating diseases
CN116903721A (zh) * 2023-06-16 2023-10-20 成都佩德生物医药有限公司 多肽pdbpe-001、其药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
ATE114332T1 (de) 1989-05-13 1994-12-15 Bayer Ag Proteinaseninhibitoren, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel.
EP0486001A1 (en) 1990-11-13 1992-05-20 Mochida Pharmaceutical Co., Ltd. Recombinant urinary trypsin inhibitor fragments and drug composition
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
WO1997033996A2 (en) 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
BRPI0509367A (pt) * 2004-03-30 2007-09-11 Glaxo Group Ltd anticorpo, fragmento de ligação de antìgeno, composição farmacêutica, métodos de tratar um paciente humano afligido com uma doença ou distúrbio, de triar um anticorpo, e de detectar hosm em uma amostra biológica, uso de um anticorpo terapêutico ou fragmento de ligação de antìgeno, medicamento, vetor, polunucleotìdeo, célula hospedeira recombinante estavelmente transformada ou transfectada, e, processo para a fabricação de um anticorpo terapêutico
KR20070041781A (ko) * 2004-08-11 2007-04-19 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인 융합 단백질
CN103665168A (zh) * 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
EP1981519B1 (en) 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
EP3053932B1 (en) * 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
CA2834626A1 (en) * 2011-04-29 2012-11-01 University Of Washington Therapeutic nuclease compositions and methods
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
JP5855239B2 (ja) * 2012-04-23 2016-02-09 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
CN103044554B (zh) 2012-05-14 2014-08-27 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
CA2939639C (en) * 2014-02-24 2023-01-24 Takeda Gmbh Uti fusion proteins

Also Published As

Publication number Publication date
EA201691702A1 (ru) 2017-01-30
JP2019187427A (ja) 2019-10-31
AU2015218704A1 (en) 2016-09-22
AU2015218704B2 (en) 2019-05-02
RS58285B1 (sr) 2019-03-29
CN106232135A (zh) 2016-12-14
CN110092837B (zh) 2024-01-02
AU2019204448B2 (en) 2021-06-10
DOP2016000202A (es) 2016-12-15
PE20170257A1 (es) 2017-03-30
EP3110434B1 (en) 2018-09-19
CR20160444A (es) 2017-04-21
AU2021225156B2 (en) 2022-11-24
KR20160141718A (ko) 2016-12-09
DK3110434T3 (en) 2019-01-14
NZ760008A (en) 2023-03-31
JP2023123763A (ja) 2023-09-05
EA202091567A1 (ru) 2021-07-30
SMT201800674T1 (it) 2019-01-11
EP3110434A1 (en) 2017-01-04
US20220127334A1 (en) 2022-04-28
MX384070B (es) 2025-03-14
AU2023200875A1 (en) 2023-04-27
CY1120997T1 (el) 2019-12-11
ZA201606327B (en) 2019-01-30
AU2021225156A1 (en) 2021-09-30
MA39347B2 (fr) 2020-05-29
CN110092837A (zh) 2019-08-06
NZ724196A (en) 2022-01-28
JO3729B1 (ar) 2021-01-31
PH12016501629A1 (en) 2017-02-06
PL3110434T3 (pl) 2019-01-31
KR102722304B1 (ko) 2024-10-28
AU2019204448A1 (en) 2019-07-11
US10351618B2 (en) 2019-07-16
MX2024000004A (es) 2024-02-20
US20160362475A1 (en) 2016-12-15
PH12016501629B1 (en) 2023-10-20
MA39347A1 (fr) 2018-06-29
KR20240155987A (ko) 2024-10-29
JP6938565B2 (ja) 2021-09-22
GEP20196970B (en) 2019-04-25
CN106232135B (zh) 2019-12-10
NZ760789A (en) 2023-03-31
SG10201708400QA (en) 2017-11-29
CL2016002136A1 (es) 2017-08-11
US20180072795A1 (en) 2018-03-15
CA3178241A1 (en) 2015-08-27
JP2017512058A (ja) 2017-05-18
MY178774A (en) 2020-10-20
UA118866C2 (uk) 2019-03-25
BR112016019390B1 (pt) 2023-11-14
BR112016019390A2 (pt) 2017-10-24
PT3110434T (pt) 2018-12-19
ES2700149T3 (es) 2019-02-14
MX2016010950A (es) 2017-04-25
JP6574431B2 (ja) 2019-09-11
LT3110434T (lt) 2018-12-27
SG11201606691QA (en) 2016-09-29
US20200040062A1 (en) 2020-02-06
EA037256B1 (ru) 2021-02-26
TWI694084B (zh) 2020-05-21
TW201630931A (zh) 2016-09-01
KR20220151005A (ko) 2022-11-11
GEAP201814277A (en) 2018-12-25
MX2019013124A (es) 2020-08-31
AR101597A1 (es) 2016-12-28
KR102461210B1 (ko) 2022-10-31
JP2022002513A (ja) 2022-01-11
CA2939639A1 (en) 2015-08-27
EP3443978A1 (en) 2019-02-20
IL247321B (en) 2020-06-30
SI3110434T1 (sl) 2019-02-28
WO2015127391A1 (en) 2015-08-27
US9856310B2 (en) 2018-01-02
IL247321A0 (en) 2016-09-29
ECSP16076535A (es) 2017-08-31
HRP20182029T1 (hr) 2019-02-08

Similar Documents

Publication Publication Date Title
AU2021225156B2 (en) UTI fusion proteins
US12473369B2 (en) Fusion protein of anti-eta antibody and tgf-beta trap and pharmaceutical composition and application thereof in method of treatment
KR20190075920A (ko) 인자 xi에 대한 신규 항체 및 그의 용도
KR20170026580A (ko) 변형된 폰 빌레브란트 인자
CN119371526A (zh) 针对人补体因子C2b的抗体及使用方法
HK40004244A (en) Uti fusion proteins
HK1232783B (en) Uti fusion proteins
HK1232783A1 (en) Uti fusion proteins
BR122023015739B1 (pt) Proteínas de fusão uti, seus usos, composição farmacêutica compreendendo a referida proteína e método de produção de uma proteína de fusão uti
KR20220062084A (ko) 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200120

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250203

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260407